Korea Institute of Science and Technology

The Green Cross Corporation

Other

Korea Research Institute of Chemical Technology

Postech Academy-industry Foundation

Neurobiogen Co., Ltd.

Megabiowood Co., Ltd

Cureverse Incorporated

Ae Nim Pae

Yong Seo Cho

Hun Yeong Koh

Kyung Il Choi

Hyunah Choo

Jae Kyun Lee

Joo Hwan Cha

Seon Hee Seo

Woo-Kyu Park

Dong Jin Kim

Hyewhon Rhim

Yun Kyung Kim

Jae Yang Kong

Gyo Chang Keum

Hee-Yoon Lee

Yong Koo Kang

Sun Joon Min

Hyun Ah Choo

Ghilsoo Nam

Ji Won Choi

Jinhwa Lee

Eun-Jung Park

Jeongmin Kim

Ki Duk Park

Ghil Soo Nam

Seul Ki Yeon

Youngsoo Kim

Jong-Hyun Park

Jung Hyun Kim

Hyun Jung Kim

Suk Hoon Kang

Suk Ho Lee

Jun Young Heo

Hee Jeong Seo

Min Ju Kim

Sang Hee Kim

Sang Eun Chae

Hee Sup Shin

ChangJoon Justin Lee

Eun Joo Roh

Myung Eun Jung

Gildon Choi

Kye Jung Shin

Heeyeong Cho

Dae Young Jeong

Eunice Eun-Kyeong Kim

Do Hee Kim

Key-Sun Kim

Hesson Chung

Chul Soo Shin

Sung Su Lim

Hoh Gyu Hahn

Seul Gi Shin

Kee Dal Nam

Hye Jin Chung

Dong Yun Shin

Hyo Jung Song

Chan Seong Cheong

Kee Hyun Choi

Woong Seo Park

Daeyoung Jeong

Moon Ho Chang

Min Ho Nam

Yoon Jee Kim

Sang Min Lim

Hyun Jung Kang

Bo Ko Jang

Eun Ji Ju

Hye Ran Kim

Ki-Nam Lee

Tae Hun Kim

Jong Hyun Park

Min Woo Lee

Jong Soo Lee

Ji Yeon Song

Ji Young Jung

Hyeon Jeong Kim

Ji Young Park

Kwang-Seop Song

Hyojin Kim

Mi-Soon Kim

Soon Bang Kang

Sung Key Jang

Younggyu Kong

In-sung Choi

Mi Young Cha

Kyung Ho Kang

Jin Hyeong Park

Chi Man Song

Ye Sun Han

You Seung Kim

Siwon Kim

Jong Yup Kim

Sun Ho Jung

Hee Sun Kim

Jae Wook Lee

Kyung-Il Choi

Cheolju Lee

Jihye Seong

Ho Kyun Han

The present invention relates to a novel halo-(3-(phenylsulfonyl)prop-1-enyl)pyridine derivative or a pharmaceutically acceptable salt thereof; a preparation method thereof; and an Nrf2 activator and a pharmaceutical composition for preventing or treating diseases induced by a decrease in Nrf2 activity, both of which comprise the same as an active ingredient.

Halo-(3-(phenylsulfonyl)prop-1-enyl)pyridine derivative and use thereof

The present disclosure relates to an &#x3b1;-aminoamide derivative compound and a pharmaceutical composition containing the same. According to various embodiments of the present disclosure, provided is a therapeutic agent which can overcome the disadvantages of existing drugs used as a MAO-B inhibitor and, specifically, reversibly inhibits MAO-B through a non-covalent bond so as to alleviate or eliminate the side effects of the existing drugs which exhibit a therapeutic effect by irreversibly acting via a covalent bond with MAO-B. Particularly, a new compound having superior stability and efficacy compared to the existing reversible MAO-B inhibitors may be provided.

Alpha-aminoamide derivative compound and pharmaceutical composition comprising same

The present disclosure relates to an &#x3b1;-aminoamide derivative compound and a pharmaceutical composition containing the same, for treating a neurodegenerative diseases.

Disclosed is a vector pair for screening tau oligomer formation, a mouse embryo introduced with the vector pair, a transgenic model mouse of neurological disease, obtained from the mouse embryo, and a method of screening a tau oligomer formation inhibitor candidate using the transgenic model mouse. More specifically, the present invention provides vector pair for screening tau oligomer formation, comprising: a first vector comprising a first tau gene, a first fluorescence protein gene and a first neuron-specific promoter; and a second vector comprising a second tau gene, a second fluorescence protein gene and a second neuron-specific promoter, wherein a protein expressed from the first fluorescence protein gene and a protein expressed from the second fluorescence protein gene bind to each other to display fluorescence, by association between a protein expressed from the first tau gene and a protein expressed from the second tau gene.

Transgenic mouse model for dementia

The present invention relates to a carbazole compound having anti-virus activity, and more particularly, to a novel compound selected from the group of consisting of a carbazole compound which shows excellent anti-proliferative efficacy against hepatitis C virus (HCV), a pharmaceutically acceptable salt thereof, a hydrate thereof, and an isomer thereof; an anti-virus pharmaceutical composition including the novel compound as an active ingredient; a pharmaceutical composition for preventing or treating liver diseases caused by hepatitis C virus; and a method of preparing the novel compound.

Carbazole compound having anti-virus activity

Disclosed is a levosimendan compound, an optically active isomer thereof, or a pharmaceutically acceptable salt thereof, which is used for the prevention and/or treatment of diseases caused by tau aggregation or phosphorylation, such as neurodegenerative diseases (e.g., Alzheimer disease). In accordance with yet another aspect of the present invention, there is provided a health functional food for preventing or treating tau aggregation-related diseases, containing a levosimendan compound or a pharmaceutically acceptable salt, stereoisomer or solvate thereof.

Levosimendan compound for preventing or treating tau-related diseases

Disclosed herein are an N-(pyrazolylmethyl)arylsulfonamide derivative useful as a calcium ion channel blocker, a pharmaceutically acceptable salt thereof, and the medicinal use thereof as a therapeutic agent using its calcium ion channel blocking effect.

Compounds capable of inhibiting voltage gated calcium ion channel, and pharmaceutical compositions comprising the same

The present invention relates to a method for preparing tetrabenazine (TBZ) and dihydrotetrabenazine (DTBZ), and more specifically to a method for preparing tetrabenazine (TBZ) and dihydrotetrabenazine (DTBZ) by using simple and short reaction processes of using 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline and 4-methyl-2-(3-(trimethylsilyl)prop-1-ene-2-yl)pentane as starting materials to sequentially perform an alkylation reaction, an Aza-Prins cyclization reaction in the presence of an oxidant and an oxidation reaction.

Method of preparing tetrabenazine and dihydrotetrabenazine

Provided is a 2-(substituted ethynyl)quinoline derivative having an mGluR5 antagonistic activity and pharmaceutically acceptable salts thereof. The compound of the present invention can be useful as a medicament for treating and preventing mGluR5 receptor-mediated diseases such as Alzheimer's disease, senile dementia, Parkinson's disease, L-DOPA-induced dyskinesia, Huntington's chorea, amyotrophic lateral sclerosis, multiple sclerosis, schizophrenia, anxiety disorder, depression, neuropathic pain, drug dependence, fragile X syndrome, autism, migraine and gastroesophageal reflux disease (GERD).

2-(substituted ethynyl)quinoline derivatives as mGLUr5 antagonists

The present invention relates to a 6-pyrazolylamido-3-substituted azabicyclo[3.1.0]hexane derivatives useful as calcium channel blockers, pharmaceutically acceptable salts thereof and medical use of the calcium channel inhibiting effect of the compounds for treatment of diseases.

6-pyrazolylamido-3-substituted azabicyclo[3.1.0]hexane compounds as calcium channel inhibitors

The present invention relates to novel arylpiperazine-containing pyrrole 3-carboxamide derivatives of formula (I) or a pharmaceutically acceptable salt thereof which is useful for preventing or treating depressive disorders. The present invention also provides a method for preparing the arylpiperazine-containing pyrrole 3-carboxamide derivatives or the pharmaceutically acceptable salt thereof, a pharmaceutical composition containing same, and a method for preventing or treating depressive disorders.

Arylpiperazine-containing pyrrole 3-carboxamide derivatives for treating depressive disorders

A novel arylpiperazine-containing imidazole 4-carboxamide derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an active ingredient for preventing or treating a depressive disorder are provided.

Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same

A novel arylpiperazine-containing purine derivatives and a pharmaceutical composition comprising the same as an active ingredient, which are useful for preventing or treating depressive disorders, are provided.

Arylpiperazine-containing purine derivatives and uses thereof

The present invention relates to a pharmaceutical composition containing one or more quinazoline compounds as an active ingredient, which has antagonistic activity against serotonin 5-HTA and is effective for the prevention and treatment of central nervous system (CNS) diseases, including emesis, nausea, alcoholism, drug abuse, depression, compulsive neurosis, anxiety, seizure, Alzheimer's disease, Parkinson's disease, Huntington's chorea, psychosis, schizophrenia, suicidal tendency, sleep disorder, appetite disorder and migraine.

Pharmaceutical compositions containing quinazoline derivatives for treating as serotonin receptor antagonist

Disclosed are novel imidazolylalkylcarbonyl derivatives useful as calcium channel modulators and a preparation method of the same. Also disclosed is a method for the treatment of diseases by administering the above compounds based on their inhibitory activity against calcium channel.

Imidazolylalkylcarbonyl derivatives as calcium channel modulators and preparation method thereof

Growing community of inventors

Seoul, South Korea

Ae Nim Pae